Your browser doesn't support javascript.
loading
Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment.
Dhakal, Ajay; Matthews, Christina M; Levine, Ellis Glenn; Salerno, Kilian Elizabeth; Zhang, Fan; Takabe, Kazuaki; Early, Amy P; Edge, Stephen B; O'Connor, Tracy; Khoury, Thaer; Young, Jessica S; Opyrchal, Mateusz.
Afiliação
  • Dhakal A; Deparmtent of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address: ajaydhakal@hotmail.com.
  • Matthews CM; Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Levine EG; Deparmtent of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Salerno KE; Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Zhang F; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Takabe K; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Early AP; Deparmtent of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Edge SB; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • O'Connor T; Deparmtent of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Khoury T; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Young JS; Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Opyrchal M; Deparmtent of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
Clin Breast Cancer ; 18(6): e1401-e1405, 2018 12.
Article em En | MEDLINE | ID: mdl-29778787
ABSTRACT

PURPOSE:

Outcome data on hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) nonamplified (HER2-) metastatic breast cancer (MBC) treated with palbociclib after treatment with everolimus are lacking. The PALOMA-3 trial, showing benefit of palbociclib plus fulvestrant compared to fulvestrant alone in HR+HER2- MBC after progression while receiving endocrine therapy excluded women previously treated with everolimus. The objective of this study was to examine outcomes of HR+HER2- MBC with prior exposure to everolimus while receiving palbociclib-based therapy. PATIENTS AND

METHODS:

A retrospective, single-institute review was conducted of HR+HER2- MBC from January 2014 to November 2016 in patients treated with palbociclib after prior treatment with everolimus. Progression-free survival (PFS) was defined as the time from initiation of palbociclib to the date of progression as determined by the treating physician based on radiologic, biochemical, and/or clinical criteria. Response rates were determined on the basis of available radiologic data. Objective response rate (ORR) was defined as the rate of any complete or partial responses; clinical benefit rate (CBR) was the rate of complete response, partial response, or stable disease for at least 24 weeks.

RESULTS:

Twenty-three patients with a mean (range) age of 68 (42-81) years were identified. Kaplan-Meier estimate showed median PFS of 2.9 months (95% confidence interval, 2.1-4.2); ORR was 0 of 23 and CBR was 4 (17.4%) of 23. In the PALOMA-3 trial, median PFS, ORR, and CBR of palbociclib cohort were 9.5 months (95% confidence interval, 9.2-11.0), 19%, and 67%, respectively.

CONCLUSION:

There is a limited clinical activity of palbociclib combinations after progression with everolimus combination therapy. Further studies are necessary to confirm these findings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Receptor ErbB-2 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article